Exchange Traded Concepts LLC Raises Position in Gilead Sciences, Inc. $GILD

Exchange Traded Concepts LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 45.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 243,532 shares of the biopharmaceutical company’s stock after buying an additional 76,432 shares during the period. Exchange Traded Concepts LLC’s holdings in Gilead Sciences were worth $29,891,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $30,000. MTM Investment Management LLC raised its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC acquired a new position in Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Millstone Evans Group LLC lifted its holdings in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GILD. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Truist Financial boosted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Stock Down 1.9%

Shares of NASDAQ GILD opened at $134.25 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The business’s 50 day moving average is $144.09 and its two-hundred day moving average is $128.57. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The firm has a market cap of $166.63 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 1.79 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.4%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the insider owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 309,280 shares of company stock valued at $44,068,850 over the last three months. 0.27% of the stock is currently owned by company insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Ouro Medicines for up to about $2.18B to expand its inflammation/immunology franchise, strengthening longer‑term growth optionality beyond established HIV and antiviral products. Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
• Positive Sentiment: Gilead has been adding immunology and CAR‑T assets to diversify its pipeline and bolster oncology exposure — a strategic shift that could lift medium/long‑term revenue growth if integration and clinical readouts succeed. Can Gilead’s Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
• Positive Sentiment: Gilead recently reported an earningsbeat and set FY‑2026 EPS guidance in the $8.45–$8.85 range, signaling stable profitability and management confidence; consensus still trails that guidance, which supports valuation. Gilead Sciences Trading / Company Report
• Positive Sentiment: Erste Group nudged up its FY‑2026 EPS forecast for Gilead, a modest analyst raise that reinforces hopes for better-than-consensus earnings next year.
• Neutral Sentiment: Analyst consensus (average brokerage recommendation) sits at a Buy — helpful context but potentially already reflected in the share price; take analyst ratings as background, not a catalyst. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Zacks highlights Gilead as a value‑oriented pick under its style scores, which may attract income/value investors but is not an immediate price driver. Here’s Why Gilead Sciences (GILD) is a Strong Value Stock
• Neutral Sentiment: Industry event notices (e.g., SK pharmteco symposium) are peripheral to Gilead’s near‑term stock movement and unlikely to be material. SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium
• Negative Sentiment: Market skepticism: analyst optimism and “Buy” consensus could be priced in, and investors may be trimming positions after recent gains (Gilead has traded near a 52‑week high in the past year), leading to downward pressure. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Deal risk and near‑term cost: the ~ $2.2B acquisition and other purchases increase upfront cash outlays and execution risk (integration, trial outcomes), which can weigh on the stock until benefits are demonstrated.
• Negative Sentiment: Technical/flow factors: trading volume is below the stock’s average and the price is below the 50‑day moving average, consistent with the current down move and limited buying momentum.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.